Enhanced expression of MAGEA-1 and MAGEA-3 on the surfaces of malignant cells might lead to more effective “killing” of the tumor cells by cytotoxic T-cell-receptor-based immunotherapeutics. This evidence concerns the gene MAGEA3 and neoplasm.